Sb611812

Sb611812

SCHEMBL6542569

CN(C)CCOc1cc(NS(=O)(=O)c2c(Cl)cc(C(F)(F)F)cc2Cl)ccc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 4/20 0.53
CACNA1H O95180 2/20 0.44
CACNA1B Q00975 2/20 0.44
PFKFB4 Q16877 1/20 0.42
ALDH1A1 P00352 3/20 0.41
HTT P42858 3/20 0.41
FABP4 P15090 1/20 0.40
MCL1 Q07820 1/20 0.40
MAPT P10636 4/20 0.39
LMNA P02545 3/20 0.39
XBP1 P17861 2/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
GAA P10253 2/20 0.37
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6135391 0.92 UTS2R (0.61) UTS2RCACNA1HCACNA1BPFKFB4ALDH1A1
SCHEMBL6542141 0.88 UTS2R (0.49) UTS2RALDH1A1HTTFABP4MAPT
SCHEMBL7249688 0.88 UTS2R (0.54) UTS2RCACNA1HCACNA1BALDH1A1MCL1
SCHEMBL7247677 0.83 UTS2R (0.49) UTS2RCACNA1BALDH1A1HTTFABP4
SCHEMBL6543128 0.81 UTS2R (0.47) UTS2RALDH1A1HTTFABP4MAPT
SCHEMBL6542701 0.80 UTS2R (0.49) UTS2RCACNA1HCACNA1BALDH1A1MAPT
SCHEMBL6542898 0.80 UTS2R (0.51) UTS2RALDH1A1HTTFABP4MAPT
SCHEMBL5230066 0.80 PFKFB4 (0.43) UTS2RCACNA1HCACNA1BPFKFB4ALDH1A1
SCHEMBL6541457 0.78 SMN1; SMN2 (0.59) UTS2RALDH1A1HTTFABP4MAPT
SCHEMBL6542198 0.78 LMNA (0.41) UTS2RALDH1A1HTTFABP4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP claimed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US claimed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP claimed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO claimed
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP disclosed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US disclosed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP disclosed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100580-A1 Urotensin-II receptor antagonists UTS2R, TMPRSS4, PLAUR UTS2R 1/4885CACNA1H 2966/4885CACNA1B 3290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.